Description

            AB Chminaca Spray

Buy AB-Chminaca Spray. A designer medication AB Chminaca Spray was discovered in 2013 in Japanese synthetic cannabis mixtures. It ranked third among synthetic cannabinoids discovered in narcotics the Drug Enforcement Agency collected in 2018.

According to reports, the (S)-enantiomer of ADB-FUBINACA, which possesses EC50 values of 1.2 nM and 3.5 nM for the CB1 and CB2 receptors, respectively, is disclosed in a 2009 Pfizer patent. Similar to SDB-001 and STS-135, ADB-FUBINACA has a carboxamide group at the 3-indazole position. Given that the only way ADB-FUBINACA differs from AB-FUBINACA is by substituting a tert-butyl group for the isopropyl group, it appears to be the result of logical drug design.

ADSB-FUB-187, an analog of ADB-FUBINACA with a more functionalize carboxamide group, was just disclose.

AB Chminaca Spray Technical Details
Name in full: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
1445583-51-6 is the CAS number.
The chemical formula is C21H23FN4O2.
Weight in Formula: 382.4
Pureness: 98%
synthesis: a tidy solid
SMILES: O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
Code for inChi: inChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)
ZSSGCSINPVBLQD-UHFFFAOYSA-N DEA is the InChi key. Timetable:

Transport & Storage Storage of information: -20°C
Delivery: Room Temperature in the US mainland; varies elsewhere
3 years of stability

Legality
ADB-FUBINACA is a Schedule I restricted drug in the US.

Metabolism
There are 23 ADB-FUBINACA Several incubations using cryopreserved human hepatocytes yielded the identification of key metabolites. Alkyl and indazole hydroxylation, terminal amide hydrolysis, following glucuronide conjugations, and dehydrogenation were the principal metabolic routes.

negative effects
There has been one death from coronary artery thrombosis related to ADB-FUBINACA poisoning.
The use of this substance was related to at least 8 additional deaths in Hungary in 2015; all of the victims were under 21 years old.